Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity

Recombinant hepatitis B vaccines are of the A2 genotype; one of ten known genotypes whose distribution varies globally. Reports of rare HBV infections in blood donors with an imbalance of non-A2 genotype HBV in vaccinated subjects have raised questions about the cross-protection afforded by HBV-A2 v...

Full description

Saved in:
Bibliographic Details
Published inExpert review of vaccines Vol. 10; no. 12; pp. 1709 - 1715
Main Authors Cassidy, Adrian, Mossman, Sally, Olivieri, Antonio, Ridder, Marc De, Leroux-Roels, Geert
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.12.2011
Expert Reviews Ltd
Informa Healthcare
Subjects
Blood donors
Children
Cross-protection
Cross-reactivity
Data processing
Development and progression
effectiveness
Genetic aspects
Genetic Variation
Genotype
Genotypes
Health aspects
Hepatitis B
Hepatitis B - blood
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B Antibodies - blood
Hepatitis B Antibodies - immunology
Hepatitis B vaccine
Hepatitis B Vaccines - administration & dosage
Hepatitis B Vaccines - genetics
Hepatitis B Vaccines - immunology
Hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B virus - immunology
Hepatitis B virus - pathogenicity
Humans
Infection
Prevention
recombinant vaccine
Reviews
Vaccination
vaccine
Vaccines
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
Online AccessGet full text

Cover

More Information
Summary:Recombinant hepatitis B vaccines are of the A2 genotype; one of ten known genotypes whose distribution varies globally. Reports of rare HBV infections in blood donors with an imbalance of non-A2 genotype HBV in vaccinated subjects have raised questions about the cross-protection afforded by HBV-A2 vaccines. Infections in HBV vaccinees were asymptomatic and transient, indicating that vaccination prevented clinical disease. Preclinical data demonstrate cross-reactivity and cross-protection by A2 vaccines against non-A2 HBV genotypes. Substantial improvements in HBV control have been demonstrated in countries with diverse genotype distribution that have introduced universal childhood HBV vaccination programs. Available data show that current HBV-A2 vaccines are highly effective in preventing infections and clinical disease caused by all known HBV genotypes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Review-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
ISSN:1476-0584
1744-8395
1744-8395
DOI:10.1586/erv.11.151